Clinical Trial Update: Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 pilot trial evaluating the HSPPC-96 vaccine in combination with ipilimumab for advanced melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HSPPC-96 (heat shock protein peptide complex-96)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Rabih Said | Conditions: Melanoma | Phase 1, Phase 2 | Status: WITHDRAWN